Robert MD - CERo Therapeutics Consultant
| CEROW Stock | 0.01 0 14.29% |
Executive
Robert MD is Consultant of CERo Therapeutics Holdings
| Age | 61 |
| Address | 201 Haskins Way, South San Francisco, CA, United States, 94080 |
| Phone | 215 731 9450 |
| Web | https://www.cero.bio |
CERo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4528) % which means that it has lost $0.4528 on every $100 spent on assets. This is way below average. CERo Therapeutics' management efficiency ratios could be used to measure how well CERo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 0.0002 in 2024, whereas Return On Tangible Assets are likely to drop (0.0003) in 2024. At this time, CERo Therapeutics' Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.19 in 2024, whereas Total Assets are likely to drop slightly above 8.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shan Wu | Viridian Therapeutics | N/A | |
| Jaakko MD | VistaGen Therapeutics | N/A | |
| Cynthia CPA | VistaGen Therapeutics | 54 | |
| Eugene Scavola | Verrica Pharmaceuticals | N/A | |
| Stephanie Franklin | Vertex Pharmaceuticals | N/A | |
| CPA CPA | Viking Therapeutics | 53 | |
| Dr MBA | Verrica Pharmaceuticals | 48 | |
| Mark Flather | VistaGen Therapeutics | N/A | |
| Colleen Mockbee | Verastem | N/A | |
| Andrew Fisher | Verona Pharma PLC | 54 | |
| Jonathan JD | Vertex Pharmaceuticals | 60 | |
| Susie CFA | Vertex Pharmaceuticals | N/A | |
| Robert MBA | Verastem | N/A | |
| Joe Bonaccorso | Verrica Pharmaceuticals | 60 | |
| Kavita Aggarwal | Verona Pharma PLC | N/A | |
| John MD | Verastem | 47 | |
| Geoffrey Barker | Viking Therapeutics | N/A | |
| Nina Devlin | Vertex Pharmaceuticals | N/A | |
| Helen Milton | Viridian Therapeutics | N/A | |
| B ASIA | Verona Pharma PLC | 57 | |
| Tara MPH | Verona Pharma PLC | 48 | |
Management Performance
| Return On Asset | -0.45 |
CERo Therapeutics Leadership Team
Elected by the shareholders, the CERo Therapeutics' board of directors comprises two types of representatives: CERo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CERo. The board's role is to monitor CERo Therapeutics' management team and ensure that shareholders' interests are well served. CERo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CERo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Consultant | ||
| Charles Carter, Treasurer, CFO | ||
| Daniel MD, Chief Officer | ||
| Christopher MBA, Interim Chairman | ||
| Brian Atwood, President Director | ||
| Lawrence MD, Cofounder Board | ||
| Andrew MBA, Chief Officer | ||
| Kristen Pierce, Chief Director |
CERo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CERo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | ||||
| Number Of Shares Shorted | 133.08 K | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (2.27) X | ||||
| Cash Flow From Operations | (1.52 K) | ||||
| Beta | -0.46 | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.